NEW YORK, March 16, 2011 /PRNewswire/ -- Nearly 100 new drugs for the treatment of hematological conditions were reported as being in the pipeline at The 52nd Annual American Society of Hematology Meeting and Exposition (ASH 2010), with 140 industry-sponsored trials evaluating drugs that have yet to make it to market being presented.
These findings and many others come from a report by Citeline, which has analyzed the presentations at ASH 2010, one of the primary events focusing on developments in the treatment of hematological diseases.
Commenting on the report, Susan Danheiser, Citeline's Senior Director for Oncology and Analytics, notes a growing trend towards the combination of early stage trial phases: "There were nearly as many Phase I/II trials presented as Phase I, by both industry and non-industry sponsors."
"A particular bright spot of the meeting was the prevalence of pipeline drugs under clinical evaluation," she continues. "Notably, nearly half (140) of the industry sponsored trials presented evaluated drugs that are currently not marketed."
Key findings from ASH 2010 covered in the report include:
* Industry sponsored just over half of the clinical trials presented, the majority of which were in phase II
* The vast majority of trials were in hematological cancers, with non-Hodgkin's lymphoma and multiple myeloma predominating
* Blended phase I/II trials figured prominently, especially for industry sponsored studies
* Celgene reported on more trials than any other industry sponsor, with the majority involving the same drug
* Biomarker endpoints were included in 20% of the trials presented
* Pipeline drugs (97) were featured in over a third of the trials sponsored by industry
Innovative pipeline spells good news for patients
Another key point to emerge from the report is the high level of innovative drugs in the pipeline, including many from smaller pharmas. Takeda, bolstered by its acquisition of Millennium two years ago, led the way in innovation, reporting on seven trials for four different pipeline drug candidates. On the heels of Takeda, were Pfizer, AstraZeneca, Novartis, Celgene and Onyx.
Daphna Halpern, Citeline's Director of Oncology is encouraged to see reporting of such a good number of pipeline drugs even though the majority are in early stages of development and are years away from reaching the market. "The majority of pipeline drug trials sponsored by industry were at the proof-of-concept stage, with 90% in Phase I - II. However, there were some pipeline drugs reported on that are close to or currently seeking first approval, which is good news for patients."